Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Clinical trial NCT05014776 · COMPLETED
Trial details
- NCT number
- NCT05014776
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-22
- Primary completion
- 2024-04-03
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.